Sun Pharma Advanced Research Company announced the grant of an exclusive license to Tripoint Therapeutics LLC, USA (Tripoint) to commercialize Elepsia™ XR 1000 mg and Elepsia™ XR 1500 mg tablets in the USA.
Under terms of the license agreement, SPARC will be eligible to receive tiered royalties ranging from 15% to 50% on net sales. Tripoint will be responsible for all US regulatory submissions and payment of annual PDUFA fees for Elepsia™ XR 1000 mg and Elepsia™ XR 1500 mg.
The initial term of the agreement shall be 5 years and may be further extended as per mutual agreement between the parties.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
